Shares of United Microelectronics Corp (ADR) (NYSE:UMC), declined – 1.14 % to $1.73, amid its last exchanging session.
United Microelectronics Corporation gives semiconductor wafer foundry arrangements. Its foundry arrangements include silicon confirmation, libraries and IP, outline check, plan for assembling, MM/RF foundry configuration pack and outline bolster manual, and outline stream reference, notwithstanding veil administrations, for example, cover investigation, IP security and information readiness, and tape-out status following.
United Microelectronics Corporation, announced that it has entered high volume creation for touch IC applications produced on UMC’s 0.11um eFlash process. The particular innovation, initially presented by UMC in late 2012 as the foundry business’ in the first place, genuine 12-volt aluminum back-end-of-line (BEoL) procedure, is created for cutting edge touch controller IC and IoT applications. Differentiation to 0.18um, 0.11um gives littler and quicker rationale gadgets for higher execution, while empowering the coordination of higher thickness inserted Flash and SRAM for utilization in microcontrollers for touch-screen results of all sizes.
Kurt Huang, senior executive of corporate advertising at UMC, said, “Touch boards have turned into the prevalent interface utilized for as of late’s hardware. A key point of preference of UMC’s touch stage arrangement is that we furnish the 0.11um eFlash with restrictive blaze large scale outline administrations to IC originators. We likewise offer the best cost versus execution by joining an aluminum BEoL procedure to serve the profoundly focused touch IC market. Furthermore, much the same as our 0.18um eFlash, support for genuine 12-volt force meets the high flag to-commotion proportion (SNR) prerequisites required for as of late’s bigger touch screens and “drifting” applications utilized amid web route on touch surfaces.”
Toward the end of Tuesday’s exchange, Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), lost – 2.70% to $6.86.
SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical organization. The Company works in two geographic fragments, checking China and whatever is left of the world (the United States and Hong Kong). The Company’s lead item ZADAXIN (thymalfasin) is utilized for the treatment of hepatitis B infection (HBV) hepatitis C (HCV) as an antibody adjuvant and certain malignancies.
SciClone Pharmaceuticals, proclaimed that Wilson W. Cheung, Chief Financial Officer, will display a corporate outline and business overhaul at the 2015 Aegis Capital Growth Conference at 11:25 am PT on Friday, October 9, 2015, at The Encore at Wynn Las Vegas.
Notes to the Stakeholders:
This article is the intellectual property of www.jbhnews.com. The purpose of penning down this article has been just to share information. Moreover, it is firmly believed that all the information that are revealed in this article are from reliable sources, however, we do not make any representations or warranties whatsoever of any kind, express or implied, as far as the completeness, accurateness, or reliability with respect to this article is concerned.
All the respectable visitors to this website are kindly advised to conduct their own independent research into individual stocks prior to making a purchase decision.
This article contains an advanced information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as well as statements regarding the forseeable frequent growth of the market for the corporation’s products, the corporation’s capability to fund its capital requirement in the close-to term and in the long term; pricing pressures; etc.
Furthermore, any statement that expresses or involves discussions with respect to forecast, expectations, beliefs, strategy, projection, objectives, aims, assumption, or future events or performance may be forward looking statements. In addition, the forward-looking statements are wholly and solely based upon expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. An easy way to identify the forward looking statements is through the use of such words as be expecting, will, foresee, guess, considered, or by statements that indicates certain actions may, could, should/might occur.